A comparative study of European rare disease and orphan drug markets
Authors:
- Alain DenisADAlain Denis
- Lut MergaertLMLut Mergaert
- Christel FostierCFChristel Fostier
- Irina CleemputICIrina Cleemput
- Steven SimoensSSSteven Simoens
- 1 October 2010
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 97 (2-3) , 173-179
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Pharmaceutical Risk-Sharing AgreementsPharmacoEconomics, 2008
- Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policyCanadian Medical Association Journal, 2006
- National Institute for Clinical Excellence and its value judgmentsBMJ, 2004